Acute heart failure

References

Key articles

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Full text  Abstract

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Full text  Abstract

Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017 Nov;33(11):1342-433.Full text  Abstract

Reference articles

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Full text  Abstract

2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Full text  Abstract

3. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007 Jun;12(2):87-90. Abstract

4. McDermott KW, Roemer M. Most frequent principal diagnoses for inpatient stays in U.S. hospitals, 2018. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2006: Statistical Brief #277.Full text

5. Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 27 Jan 2025 [Epub ahead of print].Full text  Abstract

6. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-e913.Full text  Abstract

7. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017 Apr;3(1):7-11.Full text  Abstract

8. Kimmoun A, Takagi K, Gall E, et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades. Eur J Heart Fail. 2021 Mar;23(3):420-31.Full text  Abstract

9. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005 Dec 20;112(25):3958-68.Full text  Abstract

10. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ. 2000 Jan 15;320(7228):167-70. Abstract

11. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-30. Abstract

12. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007 Jan 3;297(1):61-70.Full text  Abstract

13. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005 Jul 5;46(1):57-64. Abstract

14. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006 Nov;27(22):2725-36.Full text  Abstract

15. Gorenek B, Halvorsen S, Kudaiberdieva G, et al. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):348-57.Full text  Abstract

16. Mundisugih J, Franke KB, Tully PJ, et al. Prevalence and prognostic implication of atrial fibrillation in heart failure subtypes: systematic review and meta-analysis. Heart Lung Circ. 2023 Jun;32(6):666-77. Abstract

17. Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med. 2001 2001 Oct 22;161(19):2337-42.Full text  Abstract

18. Takizawa M, Kobayakawa N, Uozumi H, et al. A case of transient left ventricular ballooning with pheochromocytoma, supporting pathogenetic role of catecholamines in stress-induced cardiomyopathy or takotsubo cardiomyopathy. Int J Cardiol. 2007 Jan 2;114(1):e15-7. Abstract

19. Manja V, Nrusimha A, Gao Y, et al. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2023 Jan 11;109(3):168-77. Abstract

20. Rodondi N, Newman AB, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2006 Mar;8(3):217-8.Full text  Abstract

21. Berlin T, Lubina A, Levy Y, et al. Graves' disease presenting as right heart failure. Isr Med Assoc J. 2006 Mar;8(3):217-8. Abstract

22. Klatsky AL, Chartier D, Udaltsova N, et al. Alcohol drinking and risk of hospitalization for heart failure with and without associated coronary artery disease. Am J Cardiol. 2005 Aug 1;96(3):346-51. Abstract

23. Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open. 2022 Mar 1;5(3):e223849.Full text  Abstract

24. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984-1010.Full text  Abstract

25. Pandey A, Patel KV, Vaduganathan M, et al. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. JACC Heart Fail. 2018 Dec;6(12):975-82.Full text  Abstract

26. Pandey A, LaMonte M, Klein L, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017 Mar 7;69(9):1129-42.Full text  Abstract

27. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993 Nov;88(5 Pt 1):2277-83.Full text  Abstract

28. Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Full text  Abstract

29. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-9. Abstract

30. Musso G, Saba F, Cassader M, et al. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020 Nov 12;371:m4147. Abstract

31. Page RL, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.Full text  Abstract

32. Heart Failure Society of America. Executive summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194. Abstract

33. Gillespie ND, McNeill G, Pringle T, et al. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ. 1997 Mar 29;314(7085):936-40.Full text  Abstract

34. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Jun 2022 [internet publication].Full text

35. Qaseem A, Etxeandia-Ikobaltzeta I, Mustafa RA, et al. Appropriate use of point-of-care ultrasonography in patients with acute dyspnea in emergency department or inpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 2021 Jul;174(7):985-93.Full text  Abstract

36. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017 Nov;33(11):1342-433.Full text  Abstract

37. Renier W, Winckelmann KH, Verbakel JY, et al. Signs and symptoms in adult patients with acute dyspnea: a systematic review and meta-analysis. Eur J Emerg Med. 2018 Feb;25(1):3-11. Abstract

38. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002 Feb 6;287(5):628-40.Full text  Abstract

39. Khan NK, Goode KM, Cleland JG, et al. Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. Eur J Heart Fail. 2007 May;9(5):491-501. Abstract

40. Čelutkienė J, Lainscak M, Anderson L, et al. Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020 Feb;22(2):181-95.Full text  Abstract

41. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002 Jul 18;347(3):161-7.Full text  Abstract

42. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004 Feb 12;350(7):647-54.Full text  Abstract

43. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002 Jan 16;39(2):202-9. Abstract

44. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007 May 15;49(19):1943-50. Abstract

45. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007 Mar;12(1):23-36. Abstract

46. Lee KK, Doudesis D, Anwar M, et al. Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ. 2022 Jun 13;377:e068424.Full text  Abstract

47. Perna ER, Macin SM, Parras JI, et al. Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J. 2002 May;143(5):814-20. Abstract

48. Evans JDW, Dobbin SJH, Pettit SJ, et al. High-sensitivity cardiac troponin and new-onset heart failure: a systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events. JACC Heart Fail. 2018 Mar;6(3):187-97. Abstract

49. El Iskandarani M, El Kurdi B, Murtaza G, et al. Prognostic role of albumin level in heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Mar 12;100(10):e24785.Full text  Abstract

50. Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017 May 30;135(22):e1054-91.Full text  Abstract

51. Kusminsky RE. Complications of central venous catheterization. J Am Coll Surg. 2007 Apr;204(4):681-96. Abstract

52. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003 Mar 20;348(12):1123-33.Full text  Abstract

53. Smith RN, Nolan JP. Central venous catheters. BMJ. 2013 Nov 11;347:f6570.Full text  Abstract

54. Reich DL. Monitoring in anesthesia and perioperative care. Cambridge: Cambridge University Press; 2011.

55. Abbott Northwestern Hospital Internal Medicine Residency. Internal jugular central venous line. 2022 [internet publication].Full text

56. Bishop L, Dougherty L, Bodenham A, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007 Aug;29(4):261-78. Abstract

57. Practice guidelines for central venous access 2020: an updated report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2020 Jan;132(1):8-43.Full text  Abstract

58. Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth. 2000 Aug;85(2):188-91. Abstract

59. Gibson F, Bodenham A. Misplaced central venous catheters: applied anatomy and practical management. Br J Anaesth. 2013 Mar;110(3):333-46.Full text  Abstract

60. Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth. 2000 Aug;85(2):192-4. Abstract

61. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.Full text  Abstract

62. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6. Abstract

63. National Institute for Health and Care Excellence. Acute heart failure: diagnosis and management. Nov 2021 [internet publication].Full text

64. Lin Y, Chen Y, Yuan J, et al. Intravenous morphine use in acute heart failure increases adverse outcomes: a meta-analysis. Rev Cardiovasc Med. 2021 Sep 24;22(3):865-72.Full text  Abstract

65. Pratama NR, Anastasia ES, Wardhani NP, et al. Clinical outcomes of opioid administration in acute and chronic heart failure: a meta-analysis. Diabetes Metab Syndr. 2022 Oct;16(10):102636.Full text  Abstract

66. Writing Committee; Hollenberg SM, Stevenson LW, Ahmad T, et al. 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024 Sep 24;84(13):1241-67.Full text  Abstract

67. McKelvie RS, Benedict CR, Yusuf S. Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. BMJ. 1999 May 22;318(7195):1400-2. Abstract

68. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Full text  Abstract

69. Hamza M, Sattar Y, Manasrah N, et al. Meta-analysis of efficacy and safety of intravenous iron in patients with iron deficiency and heart failure with reduced ejection fraction. Am J Cardiol. 2023 Sep 1;202:119-30. Abstract

70. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.Full text  Abstract

71. Colquhoun MC, Handley AJ, Evans TR. ABC of resuscitation. 5th ed. London: BMJ Publishing Group; 2004.

72. Chrimes N, Higgs A, Hagberg CA, et al. Preventing unrecognised oesophageal intubation: a consensus guideline from the Project for Universal Management of Airways and international airway societies. Anaesthesia. 2022 Dec;77(12):1395-415.Full text  Abstract

73. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805. Abstract

74. Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023 Feb 1;44(5):411-21. Abstract

75. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022 Sep 29;387(13):1185-95.Full text  Abstract

76. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13;49(6):675-83.Full text  Abstract

77. Srivastava M, Harrison N, Caetano AFS, et al. Ultrafiltration for acute heart failure. Cochrane Database Syst Rev. 2022 Jan 21;1(1):CD013593.Full text  Abstract

78. Kivikko M, Pollesello P, Tarvasmäki T, et al. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. Int J Cardiol. 2016 Jul 15;215:26-31.Full text  Abstract

79. Geller BJ, Sinha SS, Kapur NK, et al. Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2022 Aug 9;146(6):e50-68.Full text  Abstract

80. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23;130(25):e344-426.Full text  Abstract

81. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jul 1;82(1):E1-27.Full text  Abstract

82. Reddy YNV, Borlaug BA, Gersh BJ. Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction. Circulation. 2022 Jul 26;146(4):339-57.Full text  Abstract

83. Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023 Sep;20(9):e17-91.Full text  Abstract

84. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003 May 1;348(18):1756-63.Full text  Abstract

85. Lahm T, McCaslin CA, Wozniak TC, et al. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol. 2010 Oct 26;56(18):1435-46. Abstract

86. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997 Jun 26;336(26):1860-6.Full text  Abstract

87. Peura JL, Colvin-Adams M, Francis GS, et al; American Heart Association. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012 Nov 27;126(22):2648-67.Full text  Abstract

88. Gopinathannair R, Cornwell WK, Dukes JW, et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the American Heart Association. Circulation. 2019 May 14;139(20):e967-89.Full text  Abstract

89. Cook JL, Colvin M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: ambulatory and community patient care: a scientific statement from the American Heart Association. Circulation. 2017 Jun 20;135(25):e1145-58.Full text  Abstract

90. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006 Nov 2;355(18):1873-84.Full text  Abstract

91. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-52. Abstract

92. Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023 Jun 27;81(25):2377-87. Abstract

93. Carvalho PEP, Veiga TMA, Simões E Silva AC, et al. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol. 2023 Aug;112(8):1044-55.Full text  Abstract

94. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-78.Full text  Abstract

95. Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021 Oct 19;144(16):1284-94.Full text  Abstract

96. Desai AS, Jhund PS, Claggett BL, et al. Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Dec 1;7(12):1227-34.Full text  Abstract

97. Xiang B, Zhang R, Wu X, et al. Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis. JAMA Netw Open. 2022 Sep 1;5(9):e2231963.Full text  Abstract

98. Borer JS, Böhm M, Ford I, et al; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012 Nov;33(22):2813-20.Full text  Abstract

99. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371(12):1091-9.Full text  Abstract

100. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013 May;15(5):551-9.Full text  Abstract

101. Hood WB Jr, Dans AL, Guyatt GH, et al. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2014 Apr 28;(4):CD002901.Full text  Abstract

102. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail. 2006 Feb;12(1):e86-103.Full text  Abstract

103. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28;297(12):1319-31.Full text  Abstract

104. Shang W, Zhang Y, Han D. Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: a meta-analysis. Clin Cardiol. 2022 Oct;45(10):995-1001.Full text  Abstract

105. Ma G, Ma X, Wang G, et al. Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials. BMJ Open. 2019 May 1;9(4):e025537.Full text  Abstract

106. Lu Y, Huang D, Dou C, et al. Clinical efficacy of intravenous cinepazide in the treatment of severe decompensated heart failure. Biomedical Research (India). 2012;23(4):561-5.

107. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020 May 14;382(20):1883-93.Full text  Abstract

108. De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008 Feb;10(2):201-13.Full text  Abstract

109. De Luca L, Fonarow GC, Mebazaa A, et al. Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials. Acute Card Care. 2007;9(1):10-21. Abstract

110. deGoma EM, Vagelos RH, Fowler MB, et al. Emerging therapies for the management of decompensated heart failure: from bench to bedside. J Am Coll Cardiol. 2006 Dec 19;48(12):2397-409. Abstract

111. Teerlink JR, Davison BA, Cotter G, et al. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. Eur J Heart Fail. 2020 Feb;22(2):315-29.Full text  Abstract

112. Ensor CR, Russell SD. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2010 Oct;11(14):2405-15. Abstract

113. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010 Oct 7;363(15):1419-28.Full text  Abstract

114. Teerlink JR, Felker GM, McMurray JJ, et al; ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016 Mar 29;67(12):1444-55.Full text  Abstract

115. Kuehneman T, Gregory M, de Waal D, et al. Academy of Nutrition and Dietetics evidence-based practice guideline for the management of heart failure in adults. J Acad Nutr Diet. 2018 Dec;118(12):2331-45. Abstract

116. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005 Feb 2;293(5):572-80.Full text  Abstract

117. Dec GW. Management of acute decompensated heart failure. Curr Probl Cardiol. 2007 Jun;32(6):321-66. Abstract

118. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017 Nov 14;70(20):2476-86. Abstract

119. Aguiló O, Castells X, Miró Ò, et al. The prognostic significance of bundle branch block in acute heart failure: a systematic review and meta-analysis. Clin Res Cardiol. 2023 Aug;112(8):1020-43. Abstract

120. Siurila-Waris K, Lassus J, Melin J, et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J. 2006 Dec;27(24):3011-7.Full text  Abstract

121. Benza RL, Tallaj JA, Felker GM, et al. The impact of arrhythmias in acute heart failure. J Card Fail. 2004 Aug;10(4):279-84. Abstract

Comorbidities Manager reference articles

122. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024 [internet publication].Full text

123. Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020 Oct 20;142(16 suppl 2):S366-468.Full text  Abstract

124. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004 Mar;125(3):1081-102. Abstract

125. Vasileiadis I, Alevrakis E, Ampelioti S, et al. Acid-base disturbances in patients with asthma: a literature review and comments on their pathophysiology. J Clin Med. 2019 Apr 25;8(4):563.Full text  Abstract

126. Al-Halawani R, Charlton PH, Qassem M, et al. A review of the effect of skin pigmentation on pulse oximeter accuracy. Physiol Meas. 2023 Jun 1;44(5):05TR01.Full text  Abstract

127. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 [internet publication].Full text

128. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90.Full text  Abstract

129. Saberian L, Sharif M, Aarabi M, et al. Arterial versus venous blood gas analysis comparisons, appropriateness, and alternatives in different acid/base clinical settings: a systematic review. Cureus. 2023 Jul;15(7):e41707.Full text  Abstract

130. Csoma B, Vulpi MR, Dragonieri S, et al. Hypercapnia in COPD: causes, consequences, and therapy. J Clin Med. 2022 Jun 2;11(11):3180.Full text  Abstract

131. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-705. Abstract

132. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169.Full text  Abstract

133. Veenstra P, Veeger NJGM, Koppers RJH, et al. High-flow nasal cannula oxygen therapy for admitted COPD-patients. A retrospective cohort study. PLoS One. 2022 Oct 5;17(10):e0272372.Full text  Abstract

134. Du Y, Zhang H, Ma Z, et al. High-flow nasal oxygen versus noninvasive ventilation in acute exacerbation of chronic obstructive pulmonary disease patients: a meta-analysis of randomized controlled trials. Can Respir J. 2023 Jun 30:2023:7707010.Full text  Abstract

135. Xu Z, Zhu L, Zhan J, et al. The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review. Eur J Med Res. 2021 Oct 14;26(1):122.Full text  Abstract

136. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Full text  Abstract

137. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure. Can J Cardiol. 2017 Nov;33(11):1342-433.Full text  Abstract

138. Maddox TM, Januzzi JL Jr, Allen LA, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024 Apr 16;83(15):1444-1488.Full text  Abstract

139. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012 Mar;2(1):1-138.Full text

140. Law JP, Pickup L, Townend JN, et al. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020 Mar;20(2):151-155.Full text  Abstract

141. Elenjickal EJ, Travlos CK, Marques P, et al. Anticoagulation in patients with chronic kidney disease. Am J Nephrol. 2024;55(2):146-64.Full text  Abstract

142. Hogervorst VM, Buurman BM, De Jonghe A, et al. Emergency department management of older people living with frailty: a guide for emergency practitioners. Emerg Med J. 2021 Sep;38(9):724-9. Abstract

143. British Geriatrics Society. Guideline for the care of people living with frailty undergoing elective and emergency surgery that encompasses the whole perioperative pathway. September 2021 [internet publication].Full text

144. Cesari M, Calvani R, Marzetti E. Frailty in older persons. Clin Geriatr Med. 2017 Aug;33(3):293-303. Abstract

145. Rockwood K, British Geriatrics Society. Silver book II: frailty. February 2021 [internet publication].Full text

146. Tsui C, Kim K, Spencer M. The diagnosis "failure to thrive" and its impact on the care of hospitalized older adults: a matched case-control study. BMC Geriatr. 2020 Feb 14;20(1):62.Full text  Abstract

147. Anderson K, Baraldi C, Supiano M. Identifying failure to thrive in the long term care setting. J Am Med Dir Assoc. 2012 Sep;13(7):665.e15-9. Abstract

148. Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J. 2020 Sep;23(3):210-5.Full text  Abstract

149. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95.Full text  Abstract

150. Church S, Rogers E, Rockwood K, et al. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020 Oct 7;20(1):393.Full text  Abstract

151. Falk Erhag H, Guðnadóttir G, Alfredsson J, et al. The association between the clinical frailty scale and adverse health outcomes in older adults in acute clinical settings - a systematic review of the literature. Clin Interv Aging. 2023 Feb 18:18:249-61.Full text  Abstract

152. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13. Abstract

153. Molnar F, Frank CC. Optimizing geriatric care with the GERIATRIC 5Ms. Can Fam Physician. 2019 Jan;65(1):39.Full text  Abstract

154. Tinetti M, Huang A, Molnar F. The Geriatrics 5M's: a new way of communicating what we do. J Am Geriatr Soc. 2017 Sep;65(9):2115.Full text  Abstract

155. Miller RK, Young M, Chippendale R, et al. Using the Geriatric 5Ms to teach structural and social determinants of health. J Am Geriatr Soc. 2023 Dec;71(12):3967-72. Abstract

156. Jamshed N, Gangavati A. Prioritizing the 5Ms in geriatric care: a holistic approach to care of the older adult. Am Fam Physician. 2024 Jun;109(6):498-500.Full text  Abstract

157. Conroy SP, Bardsley M, Smith P, et al. Comprehensive geriatric assessment for frail older people in acute hospitals: the HoW-CGA mixed-methods study. Southampton (UK): NIHR Journals Library; 2019 Apr.Full text  Abstract

158. Roebuck MC, Liberman JN, Gemmill-Toyama M, et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011 Jan;30(1):91-9. Abstract

159. Böhm M, Schumacher H, Laufs U, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013 Aug;166(2):306-14.e7. Abstract

160. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Full text  Abstract

161. Forsyth P, Beezer J, Bateman J. Holistic approach to drug therapy in a patient with heart failure. Heart. 2023 Jul 12;109(15):1183-91. Abstract

162. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S179-218.Full text  Abstract

163. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S158-78.Full text  Abstract

164. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317-26.Full text  Abstract

165. Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.Full text  Abstract

166. US Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Jul 2018 [internet publication].Full text

167. El-Saifi N, Moyle W, Jones C, et al. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract. 2018 Jun;31(3):322-34. Abstract

168. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S295-306.Full text  Abstract

169. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan - 2022 update. Endocr Pract. 2022 Oct;28(10):923-1049.Full text  Abstract

170. US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. March 2022 [internet publication].Full text

171. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia. 2024 Aug;67(8):1455-79.Full text  Abstract

172. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-28.Full text  Abstract

173. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021 Jun;27(6):505-37.Full text  Abstract

174. Galindo RJ, Umpierrez GE, Rushakoff RJ, et al. Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. J Diabetes Sci Technol. 2020 Nov;14(6):1035-64.Full text  Abstract

175. Avari P, Lumb A, Flanagan D, et al. Insulin pumps and hybrid close loop systems within hospital: a scoping review and practical guidance from the Joint British Diabetes Societies for Inpatient Care. J Diabetes Sci Technol. 2023 May;17(3):625-34.Full text  Abstract

176. Writing Committee, Hollenberg SM, Stevenson LW, et al. 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024 Sep 24;84(13):1241-67. Abstract

177. Natale P, Tunnicliffe DJ, Toyama T, et al. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;(5):CD015588.Full text  Abstract

178. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.Full text  Abstract

179. Goldenberg RM, Gilbert JD, Hramiak IM, et al. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab. 2019 Oct;21(10):2192-202. Abstract

180. Umapathysivam MM, Gunton J, Stranks SN, et al. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024 Jan 1;47(1):140-3.Full text  Abstract

181. Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023 Oct;11(5):e003666.Full text  Abstract

182. Honarmand K, Sirimaturos M, Hirshberg EL, et al. Society of Critical Care Medicine guidelines on glycemic control for critically ill children and adults 2024. Crit Care Med. 2024 Apr 1;52(4):e161-81.Full text  Abstract

183. Joint British Diabetes Societies for Inpatient Care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. October 2014 [internet publication].Full text

184. Lim Y, Ohn JH, Jeong J, et al. Effect of the concomitant use of subcutaneous basal insulin and intravenous insulin infusion in the treatment of severe hyperglycemic patients. Endocrinol Metab (Seoul). 2022 Jun;37(3):444-54.Full text  Abstract

185. Thammakosol K, Sriphrapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial. Diabetes Obes Metab. 2023 Mar;25(3):815-22. Abstract

186. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-314.Full text  Abstract

187. Beldhuis IE, Lam CSP, Testani JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022 Mar;145(9):693-712.Full text  Abstract

188. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-78.Full text  Abstract

189. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Full text  Abstract

190. Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019 Jun;105(12):904-10.Full text  Abstract

191. Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022 Nov 19;400(10365):1788-801.Full text  Abstract

192. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001 Jul 17;135(2):73-87. Abstract

193. Anderson WG, Berlinger N, Ragland J et al. Hospital-based prognosis and goals of care discussions with seriously ill patients: a pathway to integrate a key primary palliative care process into the workflow of hospitalist physicians and their teams. Society of Hospital Medicine and The Hastings Center, 2017 [internet publication].Full text

194. Secunda K, Wirpsa MJ, Neely KJ, et al. Use and meaning of "goals of care" in the healthcare literature: a systematic review and qualitative discourse analysis. J Gen Intern Med. 2020 May;35(5):1559-66.Full text  Abstract

195. American College of Surgeons. Best practice guidelines: geriatric trauma management. 2023 [internet publication].Full text

196. Boyd C, Smith CD, Masoudi FA, et al. Decision making for older adults with multiple chronic conditions: executive summary for the American Geriatrics Society guiding principles on the care of older adults with multimorbidity. J Am Geriatr Soc. 2019 Apr;67(4):665-73. Abstract

197. Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. N Engl J Med. 2007 Nov 1;357(18):1834-40. Abstract

198. Sulmasy LS, Bledsoe TA, ACP Ethics, Professionalism and Human Rights Committee. American College of Physicians ethics manual: seventh edition. Ann Intern Med. 2019 Jan 15;170(2_suppl):S1-32.Full text  Abstract

199. Barstow C, Shahan B, Roberts M. Evaluating medical decision-making capacity in practice. Am Fam Physician. 2018 Jul 1;98(1):40-6.Full text  Abstract

200. Farrell TW, Widera E, Rosenberg L, et al. AGS position statement: making medical treatment decisions for unbefriended older adults. J Am Geriatr Soc. 2017 Jan;65(1):14-5.Full text  Abstract

201. Pope TM, Bennett J, Carson SS, et al. Making medical treatment decisions for unrepresented patients in the ICU. An official American Thoracic Society/American Geriatrics Society policy statement. Am J Respir Crit Care Med. 2020 May 15;201(10):1182-92.Full text  Abstract

202. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94. Abstract

203. Elkind MSV, Boehme AK, Smith CJ, et al. Infection as a Stroke risk factor and determinant of outcome after stroke. Stroke. 2020 Oct;51(10):3156-68.Full text  Abstract

204. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13.Full text  Abstract

205. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 Jun;47(6):e98-169.Full text  Abstract

206. Shenvi C, Kennedy M, Austin CA, et al. Managing delirium and agitation in the older emergency department patient: the ADEPT tool. Ann Emerg Med. 2020 Feb;75(2):136-45.Full text  Abstract

207. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Abstract

208. Canadian Geriatrics Society. Update: Public launch of the geriatric 5Ms. 2017 [internet publication].Full text

209. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-73.Full text  Abstract

210. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73.Full text  Abstract

211. Han JH, Wilson A, Vasilevskis EE, et al. Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. Ann Emerg Med. 2013 Nov;62(5):457-65. Abstract

212. American College of Emergency Physicians, American Geriatrics Society, Emergency Nurses Association, et al. Geriatric emergency department guidelines. Ann Emerg Med. 2014 May;63(5):e7-25.Full text  Abstract

213. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941-8. Abstract

214. Wei LA, Fearing MA, Sternberg EJ, et al. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc. 2008 May;56(5):823-30. Abstract

215. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 Jul;29(7):1370-9. Abstract

216. Bergeron N, Dubois MJ, Dumont M, et al. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001 May;27(5):859-64. Abstract

217. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. January 2023 [internet publication].Full text

218. Inouye SK, Bogardus ST Jr, Baker DI, et al. The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. J Am Geriatr Soc. 2000 Dec;48(12):1697-706. Abstract

219. Hshieh TT, Yang T, Gartaganis SL, et al. Hospital Elder Life Program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018 Oct;26(10):1015-33. Abstract

220. Hshieh TT, Yue J, Oh E, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Intern Med. 2015 Apr;175(4):512-20.Full text  Abstract

221. Mohanty S, Rosenthal RA, Russell MM, et al. Optimal perioperative management of the geriatric patient: a best practices guideline from the American College of Surgeons NSQIP and the American Geriatrics Society. J Am Coll Surg. 2016 May;222(5):930-47. Abstract

222. American Geriatrics Society Expert Panel on Postoperative Delirium in Older Adults. American Geriatrics Society abstracted clinical practice guideline for postoperative delirium in older adults. J Am Geriatr Soc. 2015 Jan;63(1):142-50. Abstract

223. White S, Griffiths R, Baxter M, et al. Guidelines for the peri-operative care of people with dementia: guidelines from the Association of Anaesthetists. Anaesthesia. 2019 Mar;74(3):357-72.Full text  Abstract

224. Inouye SK, Kosar CM, Tommet D, et al. The CAM-S: development and validation of a new scoring system for delirium severity in 2 cohorts. Ann Intern Med. 2014 Apr 15;160(8):526-33.Full text  Abstract

225. Burton JK, Craig L, Yong SQ, et al. Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2021 Nov 26;(11):CD013307.Full text  Abstract

226. Peden CJ, Miller TR, Deiner SG, et al. Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team. Br J Anaesth. 2021 Feb;126(2):423-432.Full text  Abstract

227. The 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-81.Full text  Abstract

228. Nikooie R, Neufeld KJ, Oh ES, et al. Antipsychotics for treating delirium in hospitalized adults: a systematic review. Ann Intern Med. 2019 Oct 1;171(7):485-95.Full text  Abstract

229. Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;(12):CD013304.Full text  Abstract

230. Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019 Mar 1;2(3):e190828.Full text  Abstract

231. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Apr 1;(3):CD007726.Full text  Abstract

232. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.Full text  Abstract

233. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Full text  Abstract

234. Yamada T, Shojima N, Noma H, et al. Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Med. 2017 Jan;43(1):1-15. Abstract

235. Yatabe T, Inoue S, Sakaguchi M, et al. The optimal target for acute glycemic control in critically ill patients: a network meta-analysis. Intensive Care Med. 2017 Jan;43(1):16-28. Abstract

236. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88.Full text  Abstract

237. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8.Full text

238. American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S111-25.Full text  Abstract

239. Vue MH, Setter SM. Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia. Diabetes Spectr 1 August 2011; 24 (3): 171–7.Full text  Abstract

240. Wang C, Fang W, Li Z, et al. Clinical features, risk factors, diagnosis, and treatment of trimethoprim-sulfamethoxazole-induced hypoglycemia. Front Endocrinol (Lausanne). 2023;14:1059522.Full text  Abstract

241. McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023 Feb 15;108(3):529-62.Full text  Abstract

242. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication].Full text

243. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S231-43.Full text  Abstract

244. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21. Abstract

245. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51. Abstract

246. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Full text  Abstract

247. Silverman JJ, Galanter M, Jackson-Triche M, et al. The American Psychiatric Association practice guidelines for the psychiatric evaluation of adults. Am J Psychiatry. 2015 Aug 1;172(8):798-802.Full text  Abstract

248. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14. Abstract

249. Bauer M, Severus E, Köhler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95. Abstract

250. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013 Jul;14(5):334-85. Abstract

251. Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and cardiovascular disease. J Am Coll Cardiol. 2018 May 22;71(20):2346-59.Full text  Abstract

252. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002 Aug 14;288(6):701-9.Full text  Abstract

253. Behlke LM, Lenze EJ, Carney RM. The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases. CNS Drugs. 2020 Nov;34(11):1133-47.Full text  Abstract

254. Baldwin DS, Necking O, Schmidt SN, et al. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. J Affect Disord. 2022 Aug 15;311:588-94.Full text  Abstract

255. Harbell MW, Dumitrascu C, Bettini L, et al. Anesthetic considerations for patients on psychotropic drug therapies. Neurol Int. 2021 Nov 29;13(4):640-58.Full text  Abstract

256. Saraghi M, Golden L, Hersh EV. Anesthetic considerations for patients on antidepressant therapy - part II. Anesth Prog. 2018 Spring;65(1):60-5.Full text  Abstract

257. Hoffelt C, Gross T. A review of significant pharmacokinetic drug interactions with antidepressants and their management. Ment Health Clin. 2016 Mar 8;6(1):35-41.Full text  Abstract

258. Van Leeuwen E, van Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev. 2021 Apr 15;(4):CD013495.Full text  Abstract

259. Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I, et al. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):239-52.Full text  Abstract

260. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008 Jul;52(1):144-53. Abstract

261. Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol. 2016 Feb;13(2):175-82.Full text  Abstract

262. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20. Abstract

263. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626. Abstract

264. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013 Winter;13(4):533-40.Full text  Abstract

265. Chander WP, Singh N, Mukhiya GK. Serotonin syndrome in maintenance haemodialysis patients following sertraline treatment for depression. J Indian Med Assoc. 2011 Jan;109(1):36-7. Abstract

266. Voican CS, Corruble E, Naveau S, et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014 Apr;171(4):404-15.Full text  Abstract

267. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020 Oct 13;142(15):e214-233.Full text  Abstract

268. Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016 Jan 26;315(4):380-7.Full text  Abstract

269. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59.Full text  Abstract

270. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):80-97.Full text  Abstract

271. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40.Full text  Abstract

272. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016 Jun;11(6):4-7.Full text

273. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94. Abstract

274. Oliveira P, Ribeiro J, Donato H, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017 Mar 6:16:17.Full text  Abstract

275. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7.Full text  Abstract

276. Lapa ME, Swabe GM, Rollman BL, et al. Assessment of depression and adherence to guideline-directed medical therapies following percutaneous coronary intervention. JAMA Netw Open. 2022 Dec 1;5(12):e2246317.Full text  Abstract

277. Poletti V, Pagnini F, Banfi P, et al. The role of depression on treatment adherence in patients with heart failure-a systematic review of the literature. Curr Cardiol Rep. 2022 Dec;24(12):1995-2008.Full text  Abstract

278. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2015 Jan;78(1):25-33.Full text  Abstract

279. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(s7):S54-60.Full text  Abstract

280. Archer G, Kuh D, Hotopf M, et al. Association between lifetime affective symptoms and premature mortality. JAMA Psychiatry. 2020 Aug 1;77(8):806-13.Full text  Abstract

281. Machado MO, Veronese N, Sanches M, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 2018 Jul 20;16(1):112.Full text  Abstract

282. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Full text  Abstract

283. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services Public Health Service; May 2008 [internet publication].Full text

284. United States Public Health Service Office of the Surgeon General, National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 2020 [internet publication].Full text  Abstract

285. Streck JM, Rigotti NA, Livingstone-Banks J, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2024 May 21;(5):CD001837.Full text  Abstract

286. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;(6):CD013308.Full text  Abstract

287. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77. Abstract

288. Agrawal S, Evison M, Ananth S, et al. Medical management of inpatients with tobacco dependency. Thorax. 2024 Mar 26;79(suppl 1):3-11. Abstract

289. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.Full text  Abstract

290. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 28;(6):CD006103.Full text

291. Perret J, Yip SWS, Idrose NS, et al. Undiagnosed and 'overdiagnosed' COPD using postbronchodilator spirometry in primary healthcare settings: a systematic review and meta-analysis. BMJ Open Respir Res. 2023 Apr;10(1):e001478.Full text  Abstract

292. Joint British Diabetes Societies for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticosteroid) therapy. January 2023 [internet publication].Full text

293. Koning ACAM, van der Meulen M, Schaap D, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024 May 17;109(6):e1442-51.Full text  Abstract

294. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51.Full text  Abstract

295. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60.Full text  Abstract

296. Fardet L, Nazareth I, Whitaker HJ, et al. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013 Apr;74(4):e281-6. Abstract

297. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7.Full text  Abstract

298. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017 Aug 1;70(5):e39-110.Full text  Abstract

299. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. Abstract

300. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020 Sep 15;142(11):1028-39.Full text  Abstract

Use of this content is subject to our disclaimer